With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

Michigan’s pension bought Palantir, Intel, and CVS Health stock, while slashing an investment in Bristol Myers in the third ...